Vancouver, BC / ACCESSWIRE / May 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), the Company is pleased to announce Phytalab, in partnership with Abattis, is holding the grand opening of their analytical laboratory on Thursday May 15th from 3-8 pm in Kirkland, WA. Phytalab provides testing of Cannabis and related products in Washington State. Phytalab is opening their facility to the public for tours and a talk on Cannabis genetics and the application of genomic tools, by Dr. Jonathan Page. Dr. Page is a Canadian botanist who first published on the Cannabis genome and founder of Anandia Laboratories. We are excited to also report that Dr. Page will be speaking at 5:30 pm.
Mike Withrow, President of Abattis states "We cordially invite the public to attend our Grand Opening and to partner with us for all of your analytical and research consulting needs. Our team, including Dr. Kaleb Lund, Dr. Michelle Sexton and laboratory manager Virginia Webber comprise an impressive team with specific expertise in natural product analysis and product/process development".
Rene David, CFO stated "We are proud of our Phytalab team and their diligent preparations our first Phytalab grand opening. The event signifies Abattis' intentional diversification into the Marijuana specialty service market. It also represents a value-added income stream while we work on getting commercial license approvals in Canada."
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at www.abattis.com.
PhytaLAB is the Washington original Cannabis testing facility that set the standard for Good Laboratory Practice in the Cannabis industry. We come to this industry with extensive herbal product industry experience. We offer a range of services for growers, producer/processors and retail facilities to provide data on which to base informed business decisions. Our background in Botanical Medicine puts us first when you are looking for help in product development for specific plant chemotypes and standardization for efficacy. PhytaLAB offers consulting services to both business and regulatory entities. We can help with questions around methods, safety, packaging and labeling, and more. Please contact us for our unrivaled expertise. - See more at: http://www.thcbiz.com/directory/dispensary-resources/cannabis-analysis-labs/phytalab.html#sthash.tNplgC41.dpuf
ON BEHALF OF THE BOARD
President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [email protected]
SOURCE: Abattis Bioceuticals Corp.